Cambridge Healthtech Institute’s 3rd Annual

Autoimmune and Inflammation Drug Targets
( 自体免疫疾病和炎症药物标靶 )


This conference focuses on small molecule and peptide or macrocyclic-based agents that have the potential to be developed into oral-based therapies for the treatment of autoimmune diseases and chronic inflammation disorders. The success of biologics for autoimmune diseases coupled with rapid advances in basic research has validated many immunology-relevant signaling pathways and uncovered new intracellular molecules to target for potential new drug agents that can enter the cell. Discovering oral-based therapies, which offer patient convenience, for autoimmune and inflammation conditions is a high priority in the drug discovery industry because of the chronic nature of many autoimmune and inflammation conditions and the fact that their incidence is predicted to steadily increase due to the growing aging population. Join CHI's Autoimmune and Inflammation Drug Targets conference to network with colleagues and stay abreast of this rapidly advancing field.


Who should attend: Immunologists, Discovery Biologists, Discovery Chemists from academic and pharmaceutical departments such as inflammation, immunology, autoimmune diseases, fibrosis, infectious diseases, molecular pharmacology, cardiometabolic diseases, and molecular pharmacology


Coverage will include, but is not limited to:                                        

  • Compounds in clinical trials for IBD, Lupus, MS and more
  • Nuclear hormone receptor targets (ROR, FXR)
  • Updates on promising new intracellular drug targets (inflammasome, complement cascade, mitochondrial proteins)
  • Immuno-modulatory agents (toll-like receptor (TLR) and sting agonists)
  • 2nd generation and new intracellular kinase inhibitors (JAK, BTK, RIPK, TYK2)


* 活动内容有可能不事先告知作更动及调整。

Choose your language